Multicenter, randomized, double, parallel group, placebo-controlled trial, with valable duration of treatment, which evaluates the efficacy and safety of Siponimod (BAF3122) in patients with progressive secondary multiple sclerosis
Pathology and candidate patients
Dr. Luís Martí Bonmatí
Hospital Quirónsalud Valencia.
May 15, 2013
Hospital La Fe de Valencia
If you are interested in this clinical trial because you believe that you or a family member of yours can benefit from this new treatment.
You can request a consultation with the image diagnosis team by sending an email to the address: email@example.com